Latest Santarus Inc (SNTS) Headlines 33.6% Retu
Post# of 2
Posted On: 03/13/2014 2:08:30 PM
Latest Santarus Inc (SNTS) Headlines
33.6% Return Seen to Date on SmarTrend Santarus Call (SNTS)
Comtex SmarTrend(R) - Fri Mar 07, 9:14AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 5 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Santarus Has Returned 33.6% Since SmarTrend Recommendation (SNTS)
Comtex SmarTrend(R) - Thu Feb 27, 4:52PM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Uptrend Call Working As Santarus Stock Rises 33.6% (SNTS)
Comtex SmarTrend(R) - Thu Feb 13, 9:44AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Santarus Shares Up 33.6% Since SmarTrend's Buy Recommendation (SNTS)
Comtex SmarTrend(R) - Thu Feb 06, 9:13AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Shares of SNTS Up 33.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 15, 9:50AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 3 months, Santarus has returned 33.64% as of today's recent price of $31.96.
HEIDENHAIN Hires Parker as Product Manager for Controls
Marketwire - Tue Jan 14, 9:01AM CST
HEIDENHAIN Corporation announces the new hire of John Parker as the North American Product Manager for Controls.
Salix Pharmaceuticals announces completion of acquisition of Santarus at USD32.00 per share
M2 - Fri Jan 03, 5:32AM CST
Salix Pharmaceuticals Ltd (Nasdaq:SLXP) announced on Thursday the completion of its tender offer for all outstanding shares of common stock par value USD0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value USD0.0001 per share, of Santarus Inc (Nasdaq:SNTS), at a purchase price of USD32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.
Nasdaq stocks posting largest volume decreases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
Salix Pharmaceuticals Completes Acquisition of Santarus
Business Wire - Thu Jan 02, 3:29PM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., (NASDAQ:SNTS), at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Following the tender offer, Salix completed the acquisition of Santarus earlier today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.
RedHill Biopharma Sells ADS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:09PM CST
RedHill Biopharma recently announced that it entered into a definitive agreement with OrbiMed Israel Partners Limited Partnership the sale of American Depository Shares and warrants in a private placement transaction for $6.0 million.
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Pipeline Setback at Can-Fite BioPharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 10:50AM CST
CF101 did not fare well in a phase III study which evaluated patients with moderate-to-severe dry eye syndrome.
Relocation Plans, Patient Enrollment, Management Appointments, and Price Movements - Research Report on HCA Holdings, Opko Health, Santarus, Coronado, and Idera
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting HCA Holdings, Inc. (NYSE: HCA), Opko Health, Inc. (NYSE: OPK), Santarus, Inc. (NASDAQ: SNTS), Coronado Biosciences, Inc. (NASDAQ: CNDO), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Santarus Announces Availability of Amended Tender Offer Materials
Business Wire - Mon Dec 30, 6:00AM CST
Santarus, Inc. (NASDAQ:SNTS) today announced that on December 20, 2013 it filed an amendment (the "Amendment") to its Solicitation/Recommendation Statement on Schedule 14D-9 (the "Schedule 14D-9"), originally filed with the Securities and Exchange Commission (the "SEC") on December 3, 2013. The Schedule 14D-9 relates to the tender offer by Willow Acquisition Sub Corporation, a Delaware corporation ("Purchaser") and an indirect wholly owned subsidiary of Salix Pharmaceuticals, Ltd., a Delaware corporation ("Salix"), to purchase any and all of the issued and outstanding shares of Santarus' common stock, par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share (collectively, the "Shares"), at a purchase price of $32.00 per Share, net to the seller thereof in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 3, 2013 (as amended or supplemented from time to time, the "Offer to Purchase"), and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the "Offer"). The Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time, the "Schedule TO"), filed by Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix, and Purchaser with the SEC on December 3, 2013. The Offer to Purchase and Letter of Transmittal are filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.
Durata Progresses with Dalbavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 5:00PM CST
Durata Therapeutics continues to progress with its lead candidate, dalbavancin, which is being developed for the treatment of patients with complicated skin and soft tissue infections (cSSTI).
33.6% Return Seen to Date on SmarTrend Santarus Call (SNTS)
Comtex SmarTrend(R) - Fri Mar 07, 9:14AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 5 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Santarus Has Returned 33.6% Since SmarTrend Recommendation (SNTS)
Comtex SmarTrend(R) - Thu Feb 27, 4:52PM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Uptrend Call Working As Santarus Stock Rises 33.6% (SNTS)
Comtex SmarTrend(R) - Thu Feb 13, 9:44AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Santarus Shares Up 33.6% Since SmarTrend's Buy Recommendation (SNTS)
Comtex SmarTrend(R) - Thu Feb 06, 9:13AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 4 months, Santarus has returned 33.64% as of today's recent price of $31.96.
Shares of SNTS Up 33.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 15, 9:50AM CST
SmarTrend identified an Uptrend for Santarus (NASDAQ:SNTS) on October 21st, 2013 at $23.92. In approximately 3 months, Santarus has returned 33.64% as of today's recent price of $31.96.
HEIDENHAIN Hires Parker as Product Manager for Controls
Marketwire - Tue Jan 14, 9:01AM CST
HEIDENHAIN Corporation announces the new hire of John Parker as the North American Product Manager for Controls.
Salix Pharmaceuticals announces completion of acquisition of Santarus at USD32.00 per share
M2 - Fri Jan 03, 5:32AM CST
Salix Pharmaceuticals Ltd (Nasdaq:SLXP) announced on Thursday the completion of its tender offer for all outstanding shares of common stock par value USD0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value USD0.0001 per share, of Santarus Inc (Nasdaq:SNTS), at a purchase price of USD32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.
Nasdaq stocks posting largest volume decreases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
Salix Pharmaceuticals Completes Acquisition of Santarus
Business Wire - Thu Jan 02, 3:29PM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., (NASDAQ:SNTS), at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Following the tender offer, Salix completed the acquisition of Santarus earlier today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.
RedHill Biopharma Sells ADS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 5:09PM CST
RedHill Biopharma recently announced that it entered into a definitive agreement with OrbiMed Israel Partners Limited Partnership the sale of American Depository Shares and warrants in a private placement transaction for $6.0 million.
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Pipeline Setback at Can-Fite BioPharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 10:50AM CST
CF101 did not fare well in a phase III study which evaluated patients with moderate-to-severe dry eye syndrome.
Relocation Plans, Patient Enrollment, Management Appointments, and Price Movements - Research Report on HCA Holdings, Opko Health, Santarus, Coronado, and Idera
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting HCA Holdings, Inc. (NYSE: HCA), Opko Health, Inc. (NYSE: OPK), Santarus, Inc. (NASDAQ: SNTS), Coronado Biosciences, Inc. (NASDAQ: CNDO), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Santarus Announces Availability of Amended Tender Offer Materials
Business Wire - Mon Dec 30, 6:00AM CST
Santarus, Inc. (NASDAQ:SNTS) today announced that on December 20, 2013 it filed an amendment (the "Amendment") to its Solicitation/Recommendation Statement on Schedule 14D-9 (the "Schedule 14D-9"), originally filed with the Securities and Exchange Commission (the "SEC") on December 3, 2013. The Schedule 14D-9 relates to the tender offer by Willow Acquisition Sub Corporation, a Delaware corporation ("Purchaser") and an indirect wholly owned subsidiary of Salix Pharmaceuticals, Ltd., a Delaware corporation ("Salix"), to purchase any and all of the issued and outstanding shares of Santarus' common stock, par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share (collectively, the "Shares"), at a purchase price of $32.00 per Share, net to the seller thereof in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 3, 2013 (as amended or supplemented from time to time, the "Offer to Purchase"), and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the "Offer"). The Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time, the "Schedule TO"), filed by Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix, and Purchaser with the SEC on December 3, 2013. The Offer to Purchase and Letter of Transmittal are filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.
Durata Progresses with Dalbavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 5:00PM CST
Durata Therapeutics continues to progress with its lead candidate, dalbavancin, which is being developed for the treatment of patients with complicated skin and soft tissue infections (cSSTI).
(0)
(0)